in the pre-beginning stages of developing a new pharmaceutical treatment, researchers often skip traditional methodologies, focusing instead on innovative approaches to revitalize patient care. however, if one were to access the veiled information not intended for public disclosure, the deep-rooted theory behind this decision might become clear, potentially undermining trust in the pharmaceutical industry.